SASKATCHEWAN RN ASSOCIATION

SASKATCHEWAN REGISTERED NURSES' ASSOCIATION

RNs WITH ADDITIONAL AUTHORIZED PRACTICE
CLINICAL DECISION TOOL
DECEMBER 1, 2016

ATOPIC DERMATITIS ADULT

DEFINITION

Atopic dermatitis, also known as eczema, is an inflammatory disorder of the skin. Onset is usually in early childhood. Clients have periods of exacerbation and remission characterized by flares of ill-defined patches of erythema, scale and excoriation. Significant pruritus and generalized dry skin are usually prominent features.

IMMEDIATE CONSULTATION REQUIRED IN THE FOLLOWING SITUATIONS

- Severe disseminated atopic dermatitis (widespread lesions affecting activities of daily living and causing emotional distress)
- Severe atopic dermatitis with secondary infection
- Systemic manifestation of skin or soft tissue infection

CAUSES

- Largely unknown
- Allergy

PREDISPOSING AND RISK FACTORS

- Inherited skin sensitivity
- Cold weather
- Excessive washing
- Use of harsh soaps

HISTORY

- Typically begins in infancy
- May last throughout entire life
- Pattern in adulthood differs from that in infancy and childhood
- Periods of remission and exacerbation
- Family history of skin conditions
- Characterized chiefly by itching and scaling
- Vicious cycle of itch, scratch, rash, itch
- Usually affects face, neck, upper arms and back, flexural folds, and feet
- May be more generalized
- Specific irritating agents can be identified

- Wool, solvents, perfumed creams, lotions, and soaps may be bothersome
- Allergies, hay fever, asthma, and contact dermatitis are often present
- Hot humid or cold dry weather and emotional stress may aggravate symptoms

PHYSICAL FINDINGS

- Skin is scaly, dry, and thickened (lichenified)
- Secondary skin changes related to chronic rubbing and scratching
- Adult stage – localized and lichenified; similar distribution as childhood stage or primarily located on hands or feet. Thickened skin, increased lichenification, and excoriated and fibrotic papules are seen more commonly in the flexural areas (neck, popliteal and antecubital fossae) or face, wrists, and forearms.
- Fissures may be present
- Excoriations
- Mild redness and edema often present
- Vesicles may be present in some areas
- Lesions may be weeping
- Some areas of skin usually show chronic changes (thin skin, scarring, lichenification)
- Presence of pustular lesions suggest secondary infection

DIFFERENTIAL DIAGNOSIS

- Seborrheic dermatitis
- Dry skin (winter itch)
- Allergic contact dermatitis
- Psoriasis
- Scabies

COMPLICATIONS

- Scarring
- Secondary bacterial infection
- Chronic irritation of skin
- Side effects of medication (e.g., steroid preparations)

INVESTIGATIONS AND DIAGNOSTIC TESTS

- Lab testing is not used routinely and not recommended.
- Obtain swab for culture and sensitivity if secondary infection is suspected.

MAKING THE DIAGNOSIS

The diagnosis is based on history and physical findings, rarely biopsy.

National Institute for Health and Clinical Excellence (NICE) recommended diagnostic criteria for atopic eczema in adults:

- Diagnose atopic eczema if itchy skin condition plus ≥ 3 of:
  - Visible flexural dermatitis involving skin creases, such as elbows or knees
  - Personal history of flexural dermatitis or dry skin in last 12 months
  - Personal history of asthma or allergic rhinitis
  - May have atopic eczema on extensor surfaces rather than flexural surfaces
  - Discoid or follicular lesions may be more common

Note: Presentation may vary in clients with darker skin tones.

NICE diagnostic criteria are as follows:

- Presence of pruritus
- Chronic or chronically relapsing course, without consideration of severity, with chronicity defined as:
  - 6 months in adulthood
  - Often presence of old and new lesions simultaneously

Typical morphology and distribution described as:

- Eczematous dermatitis
- Acute lesions: erythema, exudation, papules, vesiculopapular, scales, and crusts
- Chronic lesions: infiltrated erythema, lichenification, prurigo, scales, and crusts
- Symmetrical distribution
- Commonly located on forehead, periorbital area, lips, periauricular area, neck, joint areas of limbs and trunk

- Adults - tendency to be severe on upper half of body (face, neck, anterior chest and back)

Cases that do not fulfill all 3 NICE criteria should be evaluated on basis of clinical course with tentative diagnosis of acute or chronic, nonspecific eczema.

Consider diagnosis of food allergy if:
- History of immediate food reactions

Consider diagnosis of inhalant allergy if:
- Seasonal flares of atopic dermatitis
- Asthma or allergic rhinitis
- Atopic dermatitis on face (especially around eyes)

Consider diagnosis of allergic contact dermatitis if:
- Exacerbation of previously controlled atopic eczema
- Reactions to topical treatments

MANAGEMENT AND INTERVENTIONS

Goals of Treatment
- Prevention of chronic skin changes such as pigment changes and scarring
- Relieve generalized dry skin and pruritus
- Treat patches of dermatitis to reduce inflammation and pruritus
- Reduce the risk of secondary infection
- Prevent flare-ups
- Promptly treat complication caused by irritants
- Prevent secondary infections

Appropriate Consultation
- Consult a physician/RN(NP) if no response to therapy after 1 week.

ATOPIC DERMATITIS ADULT

Non-Pharmacological Interventions

- Offer support to the client as it can be difficult to live with this irritating and cosmetically unattractive condition.
- Advise client to stop using steroid preparations once acute lesions have healed since steroids do not have any preventive benefit and may further irritate and damage skin. If maintenance is required, consult with a physician/RN(NP). Steroids should be used at the lowest effective dose for the shortest duration to minimize adverse effects.
- Assist client to identify precipitating and aggravating factors and encourage avoidance.
- If lesions are wet, promote drying and cooling with compresses qid prn (normal saline).
- If lesions are dry, promote lubrication with Glaxal base or petroleum jelly (Vaseline) bid, after bathing and prn.
- Decrease frequency of bathing.
- Use a mild soap or no soap for bathing.
- Consider a 'bleach bath' for clients who fail to respond to standard treatment, particularly those prone to recurrent infection and atopic dermatitis flares. Education on the goals, proper use, and safe storage of bleach must be provided to clients/caregivers.
    - A concentration of 0.005% bleach (sodium hypochlorite) is made by adding 120 mL (1/2 cup) of 6% household bleach to a full bathtub [estimated to be approximately 151 L (40 gallons)] of water. The amount of bleach should be adjusted based on the size of the bathtub and the amount of water in the tub.

Pharmacological Interventions

Reduce inflammation if itch is moderate or severe:

- Selection of topical therapy
  - The drier the lesion, the wetter the application, and vice versa.
    Gels and creams are used for acute, weeping eruptions. Ointments are used for dry or lichenified lesions. Lotions are used for hairy areas.

Topical Therapy

Body Area Potency	Skin Properties	Corticosteroid Potency
Face, intertriginous folds	Thin skin more absorption Consider cream, lotion, gel, or foam.	Initial treatment with low potency e.g., Hydrocortisone 1% bid-qid for 1-2 weeks
Scalp	Medium thickness skin Consider gel, foam, or lotion which are useful in hairy areas.	Initial treatment with mild potency e.g., mometasone furoate 0.1% bid for 1-2 weeks
Body	Medium thickness skin Consider cream, ointment, gel, foam, or lotion.	Initial treatment with mild potency e.g., mometasone furoate 0.1% bid for 1-2 weeks
Palms and soles	Thick skin Consider ointment.	Initial treatment with high potency e.g., betamethasone valerate 0.1% bid for 1-2 weeks

Pruritus associated with eczema is not mediated by histamine, so histamine blockade is generally ineffective. HydrOXYzine (Atarax) may provide some relief through central sedation.

Sedative effect of hydrOXYzine (Atarax) is useful to break the itch-scratch cycle:

- HydrOXYzine (Atarax) 10-25 mg orally bid and prn

- Start with 10 mg if client is small, elderly, or taking anti-anxiety medication.
- Especially useful at night.

Treatment of secondary infection

- Apply topical antibiotic preparation:
  - Mupirocin cream (Bactroban) tid for 7-10 days
  - Retapamulin (Altabax) 1% bid for 7-10 days
  - Fucidic Acid cream bid for 7-10 days

Oral antibiotics may be necessary if there are multiple lesions that appear infected:

- Cloxacillin 500 mg orally q6h for 7-10 days
  Or
- Cephalexin (Keflex) 500 mg orally q6h for 7-10 days

If methicillin-resistant *Staphylococcus aureus* (MRSA) is suspected:

- Sulfamethoxazole/Trimethoprim (SMX/TMP) 800/160 mg (DS), 1 tab orally q12h for 10 days
- Polysporin Triple Therapy topically tid

Client and Caregiver Education

- Counsel client/caregiver about appropriate use of medications (dose, frequency, application, compliance, etc.).
- Encourage proper hygiene to prevent secondary bacterial infection.
- Recommend loose-fitting cotton clothing.
- Recommend avoidance of coarse materials and wool.
- Recommend avoidance of overheating (hot showers).
- Recommend avoidance of irritants at work and at home.
- Recommend use of a soap substitute (e.g., Aveeno) and avoidance of soaps.
- Suggest that cotton gloves be worn inside rubber gloves when client works with liquids.
- Suggest that greasy lubricants (e.g., Lubriderm) be applied within minutes of leaving shower or bath to "lock in" moisture.

Monitoring and Follow-Up

- Follow-up in 1-2 weeks to assess the response. If no response, discuss use of a more potent topical steroid with a physician/RN(NP). Advise client to return sooner if signs of infection develop.

Referral

- Arrange elective follow-up with a physician/RN(NP) if there is no response to treatment.

DOCUMENTATION

- As per employer policy

REFERENCES

Atopic Dermatitis. (2013, December 16). Retrieved from https://dynamed.ebscohost.com

Buys, L. M. (2013, October 21). *Atopic dermatitis and eczema*. Retrieved from http://www.essentialevidenceplus.com

Corticosteroid: Topical. (July 2013). Retrieved from http://www.e-therapeutics.ca/

Health Canada. (2011). *First Nations & Inuit health: Clinical practice guidelines for nurses in primary care.* Ottawa, ON: Author. Retrieved from Health Canada: http://www.hc-sc.gc.ca

Kostranec, J. M., & Kolin, D. L. (Eds.). (2012). *Toronto notes: Comprehensive medical reference & review for MCCQE l & USMLE ll* (28th ed.). Toronto, ON: Toronto Notes for Medical Students.

Mayo Clinic. (2015). *Atopic dermatitis (eczema): Lifestyle and home remedies.* Retrieved from http://www.mayoclinic.org/diseases-conditions/eczema/basics/lifestyle-home-remedies/con-20032073

Papadakis, A., & McPhee, S. (2013). *Current medical diagnosis and treatment*. New York, NY: McGraw Hill Medical.

Rx Files Academic Detailing Program. (2014). *Rx Files: Drug comparison charts*. Saskatoon, SK: Saskatoon Health Region.

Weston, W., & Howe, W. (2013, July 29). *Treatment of atopic dermatitis.* Retrieved from http://www.uptodate.com

Watkins, J. (2014). Effective management of atopic eczema in adults. *Nurse Prescribing*, *12*(9), 430–435.

Watkins, J. (2015). Managing atopic eczema in adults. *Practice Nursing*, *26*(2), 62–67.

NOTICE OF INTENDED USE OF THIS CLINICAL DECISION TOOL

This SRNA Clinical Decision Tool (CDT) exists solely for use in Saskatchewan by an RN with additional authorized practice as granted by the SRNA. The CDT is current as of the date of its publication and updated every three years or as needed. A member must notify the SRNA if there has been a change in best practice regarding the CDT. This CDT does not relieve the RN with additional practice qualifications from exercising sound professional RN judgment and responsibility to deliver safe, competent, ethical and culturally appropriate RN services. The RN must consult a physician/RN(NP) when clients' needs necessitate deviation from the CDT. While the SRNA has made every effort to ensure the CDT provides accurate and expert information and guidance, it is impossible to predict the circumstances in which it may be used. Accordingly, to the extent permitted by law, the SRNA shall not be held liable to any person or entity with respect to any loss or damage caused by what is contained or left out of this CDT.

SRNA © This CDT is to be reproduced only with the authorization of the SRNA.